FOSTER CITY, Calif.--(BUSINESS WIRE)--March 8, 2006--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted traditional approval status to its once-daily antiretroviral Viread(R) (tenofovir disoproxil fumarate) and its fixed-dose product Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), which combines the company’s two antiretrovirals Emtriva(R) (emtricitabine) and Viread in a single daily tablet. Traditional approval status was granted following FDA review of 48-week data from Study 934, the second confirmatory pivotal study for Viread. The FDA previously granted accelerated approval for Viread and Truvada in October 2001 and August 2004, respectively.
